<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04651933</url>
  </required_header>
  <id_info>
    <org_study_id>EOC-LOH</org_study_id>
    <nct_id>NCT04651933</nct_id>
  </id_info>
  <brief_title>A Training Set for the HRD Model in EOC</brief_title>
  <official_title>A Training Set for the Homologous Recombination Deficiency Scoring Model With Loss of Heterozygosity Status in Epithelial Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lei Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A homologous recombination deficiency (HRD) scoring model based on loss of heterozygosity&#xD;
      (LOH) is little explored in epithelial ovarian cancer (EOC) patients. This study would&#xD;
      recruit 200 Chinese EOC patients with known BRCA1/2 mutation status and resistance to&#xD;
      platinum-based chemotherapy. A LOH-HRD model is to be constructed based on the genetic&#xD;
      testing in these patients. The mutated genes, HRD score model and their relationship with the&#xD;
      prognosis, would provide a full description of for the Chinese EOC patients, and a potential&#xD;
      explanation of platinum-resistance in such population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 26, 2020</start_date>
  <completion_date type="Anticipated">November 26, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 26, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Homologous recombination deficiency (HRD) score</measure>
    <time_frame>Two years</time_frame>
    <description>The HRD score for individual patient is a scale describing her HRD status. The score model is calculated by the analysis for loss of heterozygosity (LOH), and the minimum value is 0, but the maximun value is not available. Higher scores mean more sensitivity to poly-ADP-ribose polymerase inhibitor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Five years</time_frame>
    <description>Progression-free survival in recruited patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Five years</time_frame>
    <description>Overall survival in recruited patients</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>BRCA Mutation</condition>
  <condition>Loss of Heterozygosity</condition>
  <condition>Prognosis</condition>
  <condition>Platinum Resistance</condition>
  <condition>Homologous Recombination Deficiency</condition>
  <arm_group>
    <arm_group_label>Epithelial ovarian cancer patients sensitive to platinum based chemotherapy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Epithelial ovarian cancer patients resistant to platinum based chemotherapy</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Homologous recombination deficiency model</intervention_name>
    <description>A homologous recombination deficiency (HRD) scoring model based on loss of heterozygosity (LOH)</description>
    <arm_group_label>Epithelial ovarian cancer patients resistant to platinum based chemotherapy</arm_group_label>
    <arm_group_label>Epithelial ovarian cancer patients sensitive to platinum based chemotherapy</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples from the patients' peripheral blood and tumor tissues.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with known BRCA1/2 mutation status and resistance to platinum-based chemotherapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 years or older&#xD;
&#xD;
          -  Pathological confirmation of epithelial ovarian cancer&#xD;
&#xD;
          -  With available tumor tissues&#xD;
&#xD;
          -  Given consents to participate the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        â€¢ Not meeting all of the inclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lei Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lei Li, M.D.</last_name>
    <phone>+8613911988831</phone>
    <email>lileigh@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ming Wu, M.D.</last_name>
    <phone>+8613810224549</phone>
    <email>wuming@pumch.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lei Li</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Li, MD</last_name>
      <phone>8613911988831</phone>
      <email>lileigh@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 26, 2020</study_first_submitted>
  <study_first_submitted_qc>November 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>December 2, 2020</last_update_submitted>
  <last_update_submitted_qc>December 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Lei Li</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

